Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC boosted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 1.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,838,952 shares of the company's stock after buying an additional 28,426 shares during the quarter. Geode Capital Management LLC owned approximately 1.48% of Apellis Pharmaceuticals worth $58,699,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. National Bank of Canada FI lifted its stake in Apellis Pharmaceuticals by 266,361.5% in the 4th quarter. National Bank of Canada FI now owns 1,385,600 shares of the company's stock valued at $44,214,000 after purchasing an additional 1,385,080 shares during the last quarter. Cibc World Markets Corp bought a new position in Apellis Pharmaceuticals in the fourth quarter valued at about $41,014,000. Norges Bank bought a new stake in shares of Apellis Pharmaceuticals during the fourth quarter worth about $34,662,000. Jennison Associates LLC grew its stake in Apellis Pharmaceuticals by 51.6% during the fourth quarter. Jennison Associates LLC now owns 2,760,404 shares of the company's stock worth $88,084,000 after purchasing an additional 939,289 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in Apellis Pharmaceuticals by 23.3% in the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company's stock valued at $112,036,000 after buying an additional 735,160 shares during the period. Institutional investors and hedge funds own 96.29% of the company's stock.

Insider Buying and Selling

In other Apellis Pharmaceuticals news, CFO Timothy Eugene Sullivan sold 3,088 shares of Apellis Pharmaceuticals stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total transaction of $93,967.84. Following the transaction, the chief financial officer now directly owns 129,211 shares of the company's stock, valued at $3,931,890.73. The trade was a 2.33 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Cedric Francois sold 13,551 shares of the business's stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total transaction of $412,356.93. Following the sale, the chief executive officer now owns 418,519 shares in the company, valued at $12,735,533.17. This trade represents a 3.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 36,011 shares of company stock worth $1,059,969. Insiders own 6.80% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. The Goldman Sachs Group dropped their target price on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. Wedbush reduced their price target on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. Royal Bank of Canada decreased their price target on Apellis Pharmaceuticals from $26.00 to $25.00 and set a "sector perform" rating for the company in a report on Monday, March 3rd. HC Wainwright reiterated a "buy" rating and set a $57.00 price target on shares of Apellis Pharmaceuticals in a report on Monday, March 3rd. Finally, Scotiabank increased their target price on shares of Apellis Pharmaceuticals from $30.00 to $31.00 and gave the company a "sector perform" rating in a research report on Wednesday, April 2nd. Eight equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Apellis Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $45.59.

Apellis Pharmaceuticals Stock Up 0.2 %

NASDAQ APLS traded up $0.04 on Friday, reaching $18.20. 2,455,500 shares of the stock traded hands, compared to its average volume of 2,143,034. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The company has a market cap of $2.28 billion, a price-to-earnings ratio of -8.97 and a beta of 0.85. The company has a fifty day moving average price of $23.93 and a 200-day moving average price of $28.07. Apellis Pharmaceuticals, Inc. has a 12 month low of $17.49 and a 12 month high of $50.98.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company had revenue of $212.50 million during the quarter, compared to analyst estimates of $197.92 million. During the same period last year, the firm posted ($0.73) EPS. Apellis Pharmaceuticals's revenue for the quarter was up 45.2% compared to the same quarter last year. As a group, research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).